Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects

Diabetic Medicine

Volumn 30, Issue 10, 2013, Pages 1214-1218

  Knop, F K ^a,d   Konings, E ^b   Timmers, S ^b,c   Schrauwen, P ^b,c   Holst, J J ^a,d   Blaak, E E ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

^d Capital Region   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; PLACEBO; RESVERATROL; RESVIDA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HORMONE INHIBITION; HORMONE RESPONSE; HUMAN; MALE; OBESITY; RANDOMIZED CONTROLLED TRIAL; TEST MEAL;

ANTIOXIDANTS; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FASTING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; MALE; MIDDLE AGED; OBESITY; POSTPRANDIAL PERIOD; STILBENES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84884729090     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12231     Document Type: Article

References (17)

1. Burns J, Yokota T, Ashihara H, Lean ME, Crozier A. Plant foods and herbal sources of resveratrol. J Agric Food Chem 2002; 50: 3337-3340.
2. Szkudelska K, Szkudelski T. Resveratrol, obesity and diabetes. Eur J Pharmacol 2010; 635: 1-8.
3. Crandall JP, Oram V, Trandafirescu G, Reid M, Kishore P, Hawkins M et al. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci 2012; 67: 1307-1312.
4. Dao TM, Waget A, Klopp P, Serino M, Vachoux C, Pechere L et al. Resveratrol increases glucose-induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control. PLoS One 2011; 6: e20700.
5. Timmers S, Konings E, Bilet L, Houtkooper RH, van de WT, Goossens GH et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011; 14: 612-622.
6. Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res 2012; 32: 537-541.
7. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127: 1109-1122.
8. Shang J, Chen LL, Xiao FX, Sun H, Ding HC, Xiao H. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin 2008; 29: 698-706.
9. Zhang Y, Jayaprakasam B, Seeram NP, Olson LK, DeWitt D, Nair MG. Insulin secretion and cyclooxygenase enzyme inhibition by Cabernet Sauvignon grape skin compounds. J Agric Food Chem 2004; 52: 228-233.
10. Knop FK, Aaboe K, Vilsbøll T, Vølund A, Holst JJ, Krarup T et al. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab 2012; 14: 500-510.
11. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994; 43: 535-539.
12. Lindgren O, Carr RD, Deacon CF, Holst JJ, Pacini G, Mari A et al. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab 2011; 96: 2519-2524.
13. Ørskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma of non-insulin-dependent diabetics and non-diabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 1991; 87: 415-423.
14. Canto C, Auwerx J. PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 2009; 20: 98-105.
15. Szkudelski T. Resveratrol inhibits insulin secretion from rat pancreatic islets. Eur J Pharmacol 2006; 552: 176-181.
16. Dal-Pan A, Blanc S, Aujard F. Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity. BMC Physiol 2010; 10: 11.
17. Christensen M, Bagger JI, Vilsbøll T, Knop FK. The α-cell as target for type 2 diabetes therapy. Rev Diabet Stud 2011; 8: 369-381.